NEOS - Neos Therapeutics, Inc.
| Previous Close | 2.0100 |
| Open | 2.0000 |
| Bid | 1.9500 x 900 |
| Ask | 1.9600 x 900 |
| Day's Range | 1.9300 - 2.1300 |
| 52 Week Range | 1.4000 - 8.7000 |
| Volume | 425,478 |
| Avg. Volume | 370,829 |
| Market Cap | 97.055M |
| Beta (3Y Monthly) | 2.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6000 |
| Earnings Date | Mar 13, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.80 |
- Zacks•27 days ago
Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of NEOS earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Neos Therapeutics Inc Earnings Call
- GuruFocus.com•last month
Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. Warning! GuruFocus has detected 1 Warning Sign with NEOS. For the last quarter Neos Therapeutics Inc reported a revenue of $15.4 million, compared with the revenue of $7.11 million during the same period a year ago.
- Associated Press•last month
Neos Therapeutics: 4Q Earnings Snapshot
On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 23 cents. The pharmaceutical company posted revenue of $15.4 million in the period. For the year, the company reported ...
- Benzinga•last month
The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
- GlobeNewswire•last month
Neos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
- New commercial strategy including optimized salesforce structure, new distribution network and focus on improving net margins expected to accelerate path to profitability –.
- GlobeNewswire•last month
Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019
DALLAS and FORT WORTH, Texas, March 07, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire•last month
Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference
DALLAS and FORT WORTH, Texas, March 06, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Iamgold, Malibu Boats, Renren, 58, Neos Therapeutics, and Kimball Electronics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•3 months ago
Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
DALLAS and FORT WORTH, Texas, Jan. 30, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks•4 months ago
Teva Stock Rises on Patent Settlement With Neos Therapeutics
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
- Zacks•4 months ago
Company News For Dec 27, 2018
Companies In The News Are: TEVA,NEOS,JD,EXPE,INTC,MAR
- American City Business Journals•4 months ago
Neos, Teva settle litigation over ADHD drug
The settlement includes a licensing deal that will allow Teva to market a generic version of Cotempla beginning mid-2026.
- GlobeNewswire•4 months ago
Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
DALLAS and FORT WORTH, Texas, Dec. 26, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing.
- GlobeNewswire•5 months ago
Neos Therapeutics Announces Realignment of Commercial Organization
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing, and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it completed a strategic assessment of its commercial business and is realigning its commercial organization for its attention deficit hyperactivity disorder (ADHD) products Adzenys XR-ODT®, Cotempla XR-ODT® and Adzenys-ER™ in order to accelerate its path to profitability.
- GlobeNewswire•5 months ago
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer, effective November 30. “Vipin was chosen in a very competitive selection process and we are very excited to have him join Altimmune as President and CEO,” said Mitch Sayare, Chairman of the Board of Altimmune. “His extensive experience and success in building, managing, and financing private and public biotech companies makes him an extraordinary fit for Altimmune.
- GlobeNewswire•5 months ago
Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Neos Therapeutics Inc Earnings Call
- Zacks•5 months ago
Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Neos Therapeutics: 3Q Earnings Snapshot
The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...
- GlobeNewswire•5 months ago
Neos Therapeutics Reports Third Quarter 2018 Financial Results
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical.
- GlobeNewswire•5 months ago
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and.
- GlobeNewswire•5 months ago
Neos Therapeutics Announces Proposed Offering of Common Stock
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it has commenced an underwritten public offering of its common stock. In addition, Neos expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
